Iranian pharma company kicks off construction of plant in Azerbaijan

Iranian pharma company Darou Pakhsh Pharma Chem is building a $30 million plant in the Pirallahi Industrial Park in Azerbaijan in a JV with the government there.

An Iranian pharma company Monday broke ground on a plant it is building as a joint venture with Azerbaijan.

Iran's Darou Pakhsh Pharma Chem is building the $30 million plant in the Pirallahi Industrial Park, the Financial Tribune reports. The plant is projected to be commissioned in two years.

Darou Pakhsh Pharma Chem last year signed an agreement with the Azerbaijan Investment Company and Azersun Holding for the three-phase project. Under terms of the deal, the Iranian drugmaker will initially export drugs to Azerbaijan, then build and equip the facility and then jointly manufacture finished product in Azerbaijan.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The government in Azerbaijan is said to be anxious to create pharma joint ventures to move reduce its reliance on imported drugs to reduce costs and improve the country’s healthcare and has been offering incentives to attract foreign partners. The country imports an estimated 60% of its pharma products.

Last year, Russian drugmaker R-Pharm struck a deal with Azerbaijan Investment Company and Azerbaijani company Vita-A which will create the joint venture Hayat Farm to produce drugs. Vita-A will hold majority interest in the deal. The groups said they will build a €70 million ($75 million) plant, which they said should be producing finished pharma products by the end of 2019.

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.